Market Overview:
The global proton pump inhibitors (PPIs) market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The growth in the market can be attributed to factors such as rising prevalence of gastrointestinal disorders, increasing geriatric population, and growing demand for PPI drugs in emerging markets. Based on type, the global proton pump inhibitors (PPIs) market is segmented into pantoprazole, omeprazole, lansoprazole, esomeprazole, rabeprazole and others. Omeprazole held the largest share of the global PPIs market in 2017 and is expected to maintain its dominance during the forecast period. Pantoprazole is projected to be the fastest-growing type segment during 2018-2030 owing to its high efficacy and safety profile. Based on application, hospitals accounted for majority share of revenue generated by PPIs globally in 2017; however clinics are anticipated to witness highest growth rate over next decade due rising preference for outpatient care settings among patients suffering from gastrointestinal disorders. Other applications include long term care facilities and diagnostic centers among others segments which are collectively estimated account for less than 20% revenue share of overall PPIs market by 2030 end .
 Industry Outlook.svg)
Product Definition:
Proton pump inhibitors (PPIs) are a type of medication used to treat conditions such as acid reflux, heartburn and stomach ulcers. PPIs work by preventing the stomach from producing too much acid.
Pantoprazole:
Pantoprazole is a proton pump inhibitor (PPI) with the molecular formula C27H34N2O8 and the molecular weight of 447.4. Its chemical name is 2-Hydroxypropyl-3,5-dihydrofuran; 1,1 - Dioxoethyl pantoprazole; and others. It has a white crystalline powder appearance with a mild odor like other pharmaceutical drugs.
Omeprazole:
Omeprazole is an anti-gastric drug and was first manufactured in Japan. It was approved by the FDA for use in Europe and Japan in 1995, and for sale in the U.S.in 1997 under the brand name “Zantac”.
Application Insights:
The others segment held the largest market share of over 40% in 2017. This is due to the presence of PPI drugs with fewer side effects and higher efficacy than other PPIs. The hospital application segment is expected to grow at a lucrative rate during the forecast period owing to rising awareness regarding gastric ulcers, acid reflux disease and other associated health issues among adults in developed countries including U.S., Canada, Germany, France and UK. In addition, increasing healthcare spending will boost product demand globally during the forecast period as PPIs are considered an effective treatment for various conditions such as Zollinger-Ellison syndrome (a rare condition characterized by chronic diarrhea), gastroesophageal reflux disease (GERD) and non-erosive gastritis which involves constant inflammation of stomach lining without significant damage or ulceration to skin surface layer.
Regional Analysis:
Europe dominated the global market in terms of revenue with a share of over 35.0% in 2017. This is attributed to the high prevalence of gastric cancer and ulcers, increasing use of proton pump inhibitors for treating Helicobacter pylori infections, rising awareness about their adverse effects as well as alternatives and growing demand for cost-effective treatment options. The Asia Pacific is expected to be the fastest-growing regional market from 2018 to 2030 owing to factors such as improving economic conditions, rising healthcare expenditure & initiatives by regulatory bodies regarding H2 receptor antagonists usage in placebocontrolled trials & off-label prescriptions among others.
The Asia Pacific was followed by North America with a share of over 24.0%in 2017 due to presenceof key players suchas Gilead Sciences Inc.; Merck & Co., Inc.; Abbott Laboratories; Allergan Plc; and Pfizer Inc.
Growth Factors:
- Increasing incidence of gastrointestinal diseases: The incidence of gastrointestinal diseases is increasing globally, which is driving the demand for PPIs.
- Growing awareness about the benefits of PPIs: There is growing awareness among people about the benefits of using PPIs, which is propelling their demand.
- Rising use of over-the-counter (OTC) drugs: The use of OTC drugs is rising due to their easy availability and affordability. This is boosting the sales of PPIs as well.
- Launch of novel PPI products: Pharmaceutical companies are launching novel PPI products in order to tap into the growing market potential for these drugs.
Scope Of The Report
Report Attributes
Report Details
Report Title
Proton Pump Inhibitors (PPIs) Market Research Report
By Type
Pantoprazole, Omeprazole, Lansoprazole, Esomeprazole, Rabeprazole, Others
By Application
Hospitals, Clinics, Others
By Companies
AstraZeneca, Pfizer, Janssen, Eisai, Eli Lilly, Cadila Pharmaceuticals, Santarus, Wyeth, Changzhou Siyao Pharmaceuticals, Yangzhou Pharmaceutical, AstraZeneca
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
133
Number of Tables & Figures
94
Customization Available
Yes, the report can be customized as per your need.
Global Proton Pump Inhibitors (PPIs) Market Report Segments:
The global Proton Pump Inhibitors (PPIs) market is segmented on the basis of:
Types
Pantoprazole, Omeprazole, Lansoprazole, Esomeprazole, Rabeprazole, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Pfizer
- Janssen
- Eisai
- Eli Lilly
- Cadila Pharmaceuticals
- Santarus
- Wyeth
- Changzhou Siyao Pharmaceuticals
- Yangzhou Pharmaceutical
- AstraZeneca
 Market Overview.svg)
Highlights of The Proton Pump Inhibitors (PPIs) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Pantoprazole
- Omeprazole
- Lansoprazole
- Esomeprazole
- Rabeprazole
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Proton Pump Inhibitors (PPIs) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Proton pump inhibitors (PPIs) are a class of medications that work by inhibiting the action of the proton pump, an enzyme responsible for breaking down stomach acid. PPIs are generally safe and effective, but they can cause serious side effects if taken in large doses or for a long period of time. These side effects may include ulcers, heart problems, and even death.
Some of the major players in the proton pump inhibitors (ppis) market are AstraZeneca, Pfizer, Janssen, Eisai, Eli Lilly, Cadila Pharmaceuticals, Santarus, Wyeth, Changzhou Siyao Pharmaceuticals, Yangzhou Pharmaceutical, AstraZeneca.
The proton pump inhibitors (ppis) market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Proton Pump Inhibitors (PPIs) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Proton Pump Inhibitors (PPIs) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Proton Pump Inhibitors (PPIs) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Proton Pump Inhibitors (PPIs) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Proton Pump Inhibitors (PPIs) Market Size & Forecast, 2018-2028
4.5.1 Proton Pump Inhibitors (PPIs) Market Size and Y-o-Y Growth
4.5.2 Proton Pump Inhibitors (PPIs) Market Absolute $ Opportunity
Chapter 5 Global Proton Pump Inhibitors (PPIs) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Proton Pump Inhibitors (PPIs) Market Size Forecast by Type
5.2.1 Pantoprazole
5.2.2 Omeprazole
5.2.3 Lansoprazole
5.2.4 Esomeprazole
5.2.5 Rabeprazole
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Proton Pump Inhibitors (PPIs) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Proton Pump Inhibitors (PPIs) Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Proton Pump Inhibitors (PPIs) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Proton Pump Inhibitors (PPIs) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Proton Pump Inhibitors (PPIs) Analysis and Forecast
9.1 Introduction
9.2 North America Proton Pump Inhibitors (PPIs) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Proton Pump Inhibitors (PPIs) Market Size Forecast by Type
9.6.1 Pantoprazole
9.6.2 Omeprazole
9.6.3 Lansoprazole
9.6.4 Esomeprazole
9.6.5 Rabeprazole
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Proton Pump Inhibitors (PPIs) Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Proton Pump Inhibitors (PPIs) Analysis and Forecast
10.1 Introduction
10.2 Europe Proton Pump Inhibitors (PPIs) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Proton Pump Inhibitors (PPIs) Market Size Forecast by Type
10.6.1 Pantoprazole
10.6.2 Omeprazole
10.6.3 Lansoprazole
10.6.4 Esomeprazole
10.6.5 Rabeprazole
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Proton Pump Inhibitors (PPIs) Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Proton Pump Inhibitors (PPIs) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Proton Pump Inhibitors (PPIs) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Proton Pump Inhibitors (PPIs) Market Size Forecast by Type
11.6.1 Pantoprazole
11.6.2 Omeprazole
11.6.3 Lansoprazole
11.6.4 Esomeprazole
11.6.5 Rabeprazole
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Proton Pump Inhibitors (PPIs) Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Proton Pump Inhibitors (PPIs) Analysis and Forecast
12.1 Introduction
12.2 Latin America Proton Pump Inhibitors (PPIs) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Proton Pump Inhibitors (PPIs) Market Size Forecast by Type
12.6.1 Pantoprazole
12.6.2 Omeprazole
12.6.3 Lansoprazole
12.6.4 Esomeprazole
12.6.5 Rabeprazole
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Proton Pump Inhibitors (PPIs) Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Proton Pump Inhibitors (PPIs) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Proton Pump Inhibitors (PPIs) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Proton Pump Inhibitors (PPIs) Market Size Forecast by Type
13.6.1 Pantoprazole
13.6.2 Omeprazole
13.6.3 Lansoprazole
13.6.4 Esomeprazole
13.6.5 Rabeprazole
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Proton Pump Inhibitors (PPIs) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Proton Pump Inhibitors (PPIs) Market: Competitive Dashboard
14.2 Global Proton Pump Inhibitors (PPIs) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Pfizer
14.3.3 Janssen
14.3.4 Eisai
14.3.5 Eli Lilly
14.3.6 Cadila Pharmaceuticals
14.3.7 Santarus
14.3.8 Wyeth
14.3.9 Changzhou Siyao Pharmaceuticals
14.3.10 Yangzhou Pharmaceutical
14.3.11 AstraZeneca
